performed a retrospective study and found mutations affecting TET2/IDH (95% [50/85] vs. 38% [122/319], p < 0.01) and SRSF2 (31% [26/85] vs. 15% [47/319], p < 0.01) to be more frequent in MDS/CMML patients with SIADs than those without SIADs [6]. Here, IDH2 is linked to chronic myelomonocytic leukemia.